Literature DB >> 16879084

AMP-activated protein kinase as a drug target.

D Grahame Hardie1.   

Abstract

The AMP-activated protein kinase (AMPK) system is a regulator of energy balance at both the cellular and whole-body levels that, once activated by low energy status, effects a switch from ATP-consuming anabolic pathways to ATP-producing catabolic pathways. It now appears to be the major target for two existing classes of drug used to treat type 2 diabetes, i.e., the biguanides and thiazolidinediones. However, in both cases these activate AMPK indirectly, and an interesting question concerns whether a drug that directly activated AMPK would retain the therapeutic benefits of the existing drugs while eliminating unwanted side effects. AMPK activators also now have potential as anticancer drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16879084     DOI: 10.1146/annurev.pharmtox.47.120505.105304

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  165 in total

1.  Endoplasmic reticulum oxidase 1α is critical for collagen secretion from and membrane type 1-matrix metalloproteinase levels in hepatic stellate cells.

Authors:  Mizuki Fujii; Akihiro Yoneda; Norio Takei; Kaori Sakai-Sawada; Marina Kosaka; Kenjiro Minomi; Atsuro Yokoyama; Yasuaki Tamura
Journal:  J Biol Chem       Date:  2017-08-03       Impact factor: 5.157

Review 2.  Cardiovascular impact of drugs used in the treatment of diabetes.

Authors:  Chris R Triggle; Hong Ding
Journal:  Ther Adv Chronic Dis       Date:  2014-11       Impact factor: 5.091

Review 3.  Cancer cell signaling pathways targeted by spice-derived nutraceuticals.

Authors:  Bokyung Sung; Sahdeo Prasad; Vivek R Yadav; Bharat B Aggarwal
Journal:  Nutr Cancer       Date:  2011-12-09       Impact factor: 2.900

4.  Protein kinase A contributes to the negative control of Snf1 protein kinase in Saccharomyces cerevisiae.

Authors:  LaKisha Barrett; Marianna Orlova; Marcin Maziarz; Sergei Kuchin
Journal:  Eukaryot Cell       Date:  2011-12-02

Review 5.  Metformin pathways: pharmacokinetics and pharmacodynamics.

Authors:  Li Gong; Srijib Goswami; Kathleen M Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-11       Impact factor: 2.089

6.  Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice.

Authors:  Konstantin Tsoyi; Hwa Jin Jang; Irina Tsoy Nizamutdinova; Young Min Kim; Young Soo Lee; Hye Jung Kim; Han Geuk Seo; Jae Heun Lee; Ki Churl Chang
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

7.  Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden.

Authors:  Herbert Y Meltzer
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

8.  Heme oxygenase-1 induction remodels adipose tissue and improves insulin sensitivity in obesity-induced diabetic rats.

Authors:  Angelique Nicolai; Ming Li; Dong Hyun Kim; Stephen J Peterson; Luca Vanella; Vincenzo Positano; Amalia Gastaldelli; Rita Rezzani; Luigi F Rodella; George Drummond; Claudia Kusmic; Antonio L'Abbate; Attallah Kappas; Nader G Abraham
Journal:  Hypertension       Date:  2009-01-26       Impact factor: 10.190

Review 9.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

Review 10.  Pharmacogenetics of metformin response: a step in the path toward personalized medicine.

Authors:  Marc L Reitman; Eric E Schadt
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.